Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30176791 | 1.00 | CA12 (0.54) | CA12CA9CA1CA3CA4 | |
| Acetic Acid SCHEMBL9409744 | 0.89 | HRH4 (0.47) | CA12CA9CA1CA3CA4 | |
| SCHEMBL347122 | 0.85 | CA12 (0.60) | CA12CA9CA1CA3CA4 | |
| SCHEMBL25904886 | 0.79 | PDE3B (0.46) | CA12CA9CA1CA3CA4 | |
| SCHEMBL17951770 | 0.77 | MAPK1 (0.68) | CA12CA9CA1CA3CA4 | |
| SCHEMBL16627567 | 0.75 | METAP2 (0.46) | AHRMETAP2NOS1DYRK1AHRH4 | |
| SCHEMBL252706 | 0.74 | CA12 (0.54) | CA12CA9CA1CA3CA4 | |
| SCHEMBL708122 | 0.74 | DAO (0.56) | CA12CA9CA1CA3CA4 | |
| SCHEMBL1286631 | 0.74 | CA12 (0.54) | CA12CA9CA1CA3CA4 | |
| SCHEMBL31743074 | 0.74 | F11 (0.74) | CA12CA9CA1CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119841811-A | Quinolone compound and preparation method and application thereof | 复旦大学 | 2025-04-18 | — | — | CN | claimed |
| CN-115521298-A | Preparation method of brexpiprazole | 江苏慧聚药业股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| EP-4583874-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2025-07-16 | — | — | EP | disclosed |
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4548972-A2 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2025-05-07 | — | — | EP | disclosed |
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119841811-A | Quinolone compound and preparation method and application thereof | 复旦大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-3744714-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-0583136-B1 | Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders | KISSEI PHARMACEUTICAL (JP) | 1997-10-08 | — | — | EP | disclosed |
| US-5616712-A | SKIN DISORDERS; ANTICARCINOGENIC AND -INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; | ALLERGAN (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996036609-A1 | QUINOLYL-ETHYNYL DERIVATIVES HAVING RETINOID-LIKE ACTIVITY | ALLERGAN (US) | 1996-11-21 | — | — | WO | disclosed |
| US-5294718-A | Platelet aggregation inhibitors; antiischemic agents; side effect reduction | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| EP-0583136-A2 | Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders | Kissei Pharmaceutical Co., Ltd. (JP) | 1994-02-16 | — | — | EP | disclosed |
| US-5216148-A | Treating, preventing neoplasms, dermatoses, aging of skin | HOFFMANN-LA ROCHE INC. (US) | 1993-06-01 | — | — | US | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| CN-85100796-A | The preparation method of qualone derivative | — | 1986-10-01 | — | — | CN | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | CA12 4719/4885CA9 4407/4885CA1 4782/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | CA12 4083/4885CA9 4188/4885CA1 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.